| Mr Milo Lavon Hibbert, MD | |
|
610 Sunset Dr, La Grande, OR 97850-1248 | |
| (541) 963-2216 | |
| Not Available |
| Full Name | Mr Milo Lavon Hibbert |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 47 Years |
| Location | 610 Sunset Dr, La Grande, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689604233 | NPI | - | NPPES |
| 930505325014 | Other | OR | EMPLOYER ID NUMBER |
| H1254 01 | Other | OR | PACIFIC SOURCE |
| 212001 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | MD11673 (Oregon) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Grande Ronde Hospital Inc | 0547170789 | 74 |
News Archive
Helicos BioSciences Corporation announced today its operational, technical and scientific highlights for the quarter ended September 30, 2009.
The Center for Neurodegenerative Disease Research (CNDR) at the University of Pennsylvania has received a grant expected to total $18.1 million to study the underlying genetic mechanisms that cause Alzheimer's Disease, Dementia, and Parkinson's Disease to progress as well as how those mechanisms are related to each other and to the cell-to-cell spread of these disease proteins.
The U.S. federal government is preparing to launch a set of sweeping new regulations that will have a major impact on how biomedical researchers and social scientists work. It will require researchers to change how they get ethics approval, how they collect informed consent from participants, and more.
Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, today announced the clearance of the Investigational New Drug application by the United States Food and Drug Administration to conduct a Phase 2 study of ADXS-HPV (ADXS11-001) alone or in combination with Incyte Corporation's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360), for the treatment of Stage I-IIIb human papillomavirus (HPV)-associated cervical cancer.
› Verified 7 days ago
| Entity Name | Grande Ronde Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467446195 PECOS PAC ID: 0547170789 Enrollment ID: O20031124000758 |
News Archive
Helicos BioSciences Corporation announced today its operational, technical and scientific highlights for the quarter ended September 30, 2009.
The Center for Neurodegenerative Disease Research (CNDR) at the University of Pennsylvania has received a grant expected to total $18.1 million to study the underlying genetic mechanisms that cause Alzheimer's Disease, Dementia, and Parkinson's Disease to progress as well as how those mechanisms are related to each other and to the cell-to-cell spread of these disease proteins.
The U.S. federal government is preparing to launch a set of sweeping new regulations that will have a major impact on how biomedical researchers and social scientists work. It will require researchers to change how they get ethics approval, how they collect informed consent from participants, and more.
Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, today announced the clearance of the Investigational New Drug application by the United States Food and Drug Administration to conduct a Phase 2 study of ADXS-HPV (ADXS11-001) alone or in combination with Incyte Corporation's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360), for the treatment of Stage I-IIIb human papillomavirus (HPV)-associated cervical cancer.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Milo Lavon Hibbert, MD 610 Sunset Dr, La Grande, OR 97850-1248 Ph: (541) 963-2216 | Mr Milo Lavon Hibbert, MD 610 Sunset Dr, La Grande, OR 97850-1248 Ph: (541) 963-2216 |
News Archive
Helicos BioSciences Corporation announced today its operational, technical and scientific highlights for the quarter ended September 30, 2009.
The Center for Neurodegenerative Disease Research (CNDR) at the University of Pennsylvania has received a grant expected to total $18.1 million to study the underlying genetic mechanisms that cause Alzheimer's Disease, Dementia, and Parkinson's Disease to progress as well as how those mechanisms are related to each other and to the cell-to-cell spread of these disease proteins.
The U.S. federal government is preparing to launch a set of sweeping new regulations that will have a major impact on how biomedical researchers and social scientists work. It will require researchers to change how they get ethics approval, how they collect informed consent from participants, and more.
Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, today announced the clearance of the Investigational New Drug application by the United States Food and Drug Administration to conduct a Phase 2 study of ADXS-HPV (ADXS11-001) alone or in combination with Incyte Corporation's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360), for the treatment of Stage I-IIIb human papillomavirus (HPV)-associated cervical cancer.
› Verified 7 days ago
Ralph Clyde Oler, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 709 Aquarius Way, La Grande, OR 97850 Phone: 541-962-8420 | |
Stacy Leilani Whitaker, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 900 Sunset Dr, La Grande, OR 97850 Phone: 541-963-1883 Fax: 541-963-1837 | |
Dr. Dawn C Knight, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 610 Sunset, La Grande, OR 97850 Phone: 541-663-3175 Fax: 318-387-7919 |